

Neola Medical Q3 - Entering the clinical validation phase

Redeye provides an update following Neola Medical's Q3 2024 report. The report largely aligned with our expectations as no sales were disclosed, and costs were within the margins. The company has now entered the clinical validation phase, which makes us expect an interesting and important year ahead.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Neola Medical Q3 - Entering the clinical validation phase](#)